EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

First Case of HIV Seroconversion With Integrase Resistance Mutations on Long-Acting Cabotegravir for Prevention in Routine Care

Catherine A Koss iD, Monica Gandhi iD, Elias K Halvas, Hideaki Okochi, Carolyn Chu, David V Glidden, Lisa Georgetti Gomez, Amy L Heaps, Amy A Conroy, Michael Tran, Cory Shetler, Dianna Hoeth und 11 weitere

Open Forum Infectious Diseases · 30.08.2024 · 11 (9)

DOI: 10.1093/ofid/ofae468 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 26.08.2024. Verfasst von Catherine A Koss und 22 weiteren Autor:innen. Beteiligte Einrichtung: University of California, San Francisco, San Francisco, California, USA. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, US National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Long-acting cabotegravir (CAB-LA) is highly effective for HIV prevention, but delayed HIV diagnoses and integrase strand transfer inhibitor (INSTI) resistance were observed in trials. We report the first case in routine clinical care of HIV infection on CAB-LA with INSTI resistance.

Methods

The SeroPrEP study enrolls individuals in the United States who acquire HIV on pre-exposure prophylaxis modalities to assess diagnostics, antiretroviral (ARV) drug levels, resistance, and treatment outcomes. Resistance mutations in full-length HIV-1 integrase were identified by single-genome sequencing (SGS). Cabotegravir concentrations in plasma and hair segments were measured by liquid chromatography–tandem mass spectrometry.

Results

A 23-year-old gender-nonbinary person, male at birth, restarted CAB-LA 6 months after discontinuation due to losing insurance. Prior to restart, HIV-1 RNA was not detected, but 20 days elapsed before CAB-LA injection. After the second CAB-LA injection, HIV antigen/antibody returned reactive (HIV-1 RNA 451 copies/mL). SGS of plasma HIV-1 RNA identified INSTI mutation Q148R in 2/24 sequences 2 days postdiagnosis; commercial genotype failed amplification. Cabotegravir hair concentration was 0.190 ng/mg 2 weeks prediagnosis; plasma cabotegravir was high (3.37 μg/mL; ∼20× PA-IC90) 14 days postdiagnosis. Viral suppression was maintained for 6 months on darunavir/cobicistat/emtricitabine/tenofovir alafenamide, then switched to doravirine + emtricitabine/tenofovir alafenamide due to nausea.

Conclusions

In this first case of HIV infection on CAB-LA with INSTI resistance in routine care, cabotegravir resistance was detected only with a sensitive research assay. Accelerated pathways to minimize time between HIV testing and CAB-LA initiation are needed to optimize acute HIV detection and mitigate resistance risk. Sustained product access regardless of insurance is imperative to reduce HIV infections on CAB-LA.

Schlagwörter

Stichwörter der Autor:innen

HIV preventionbreakthrough infectionpharmacokineticspre-exposure prophylaxisresistance

Autor:innen und Institutionen

  • University of California, San Francisco, San Francisco, California, USA.
  • University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Men's Health Foundation, Los Angeles, California, USA.
  • Global Programs for Research and Training, Nairobi, Kenya.
  • University of Washington, Seattle, Washington, USA.
  • Centre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya.

ORCID-Profile: Catherine A Koss, Monica Gandhi

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • US National Institutes of Health
  • UCSF-Bay Area Center for AIDS Research

Zitieren

APA

Koss, C. A., Gandhi, M., Halvas, E. K., Okochi, H., Chu, C., Glidden, D. V., Georgetti Gomez, L., Heaps, A. L., Conroy, A. A., Tran, M., Shetler, C., Hoeth, D., Kuncze, K., Louie, A., Rivera Garza, H., Wafula Mugoma, E., Penrose, K. J., Chohan, B. H., Ayieko, J. O., …, & Parikh, U. M. (2024). First Case of HIV Seroconversion With Integrase Resistance Mutations on Long-Acting Cabotegravir for Prevention in Routine Care. Open Forum Infectious Diseases, 11(9). https://doi.org/10.1093/ofid/ofae468

Vancouver

Koss CA, Gandhi M, Halvas EK, Okochi H, Chu C, Glidden DV, et al. First Case of HIV Seroconversion With Integrase Resistance Mutations on Long-Acting Cabotegravir for Prevention in Routine Care. Open Forum Infectious Diseases. 2024;11(9). doi:10.1093/ofid/ofae468

BibTeX
@article{Koss2024,
  author = {Koss, Catherine A and Gandhi, Monica and Halvas, Elias K and Okochi, Hideaki and Chu, Carolyn and Glidden, David V and Georgetti Gomez, Lisa and Heaps, Amy L and Conroy, Amy A and Tran, Michael and Shetler, Cory and Hoeth, Dianna and Kuncze, Karen and Louie, Alexander and Rivera Garza, Hana and Wafula Mugoma, Erick and Penrose, Kerri J and Chohan, Bhavna H and Ayieko, James O and Mills, Anthony and Patel, Rupa R and Mellors, John W and Parikh, Urvi M},
  title = {First Case of HIV Seroconversion With Integrase Resistance Mutations on Long-Acting Cabotegravir for Prevention in Routine Care},
  journal = {Open Forum Infectious Diseases},
  year = {2024},
  volume = {11},
  number = {9},
  doi = {10.1093/ofid/ofae468}
}
Kostenlos starten →